These cells show superior proliferative and effector functions against tumors, with an underlying mechanism dependent on type I IFN signaling. Our data may ultimately give new understanding into cancer immunotherapy that utilizes FLT3L preconditioning of naive T cells (Fig. 6). The gene discussed is FLT3LG; the disease is cancer.